Print this page
lung
-
A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer.
Protocol: 082501Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLAA*02:01-Positive Participants with Previously Treated Advanced Melanoma.
Protocol: 092203Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-ZZFX (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Protocol: 102301Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Other Female Genital -
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial.
Protocol: 102403Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site
Other Female Genital -
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-Sensitive Recurrent Ovarian Cancer (TroFuse-022/GOG-3103/ENGOT-ov84).
Protocol: 102501Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Other Female Genital -
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR alpha-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Protocol: 102502Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Ovary -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints
Lung -
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma.
Protocol: 112303Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma -
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT).
Protocol: 112504Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Any Site -
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB).
Protocol: 112505Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lung -
ScreenNJ Resource and Evaluation Unit
Protocol: 131820Applicable Disease Sites: Colon
Lung -
TELEhealth Shared decision-making COaching for lung cancer screening in Primary carE (TELESCOPE).
Protocol: 132207Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Lung -
TELEhealth Shared decision-making COaching for lung cancer screening in Primary care (TELESCOPE) for Hispanics
Protocol: 132512Principal Investigator:
- Evelyn Arana
Applicable Disease Sites: Lung -
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases.
Protocol: 142403Applicable Disease Sites: Brain and Nervous System